Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial.

Abstract

A multi-institutional, phase 1 dose-escalation trial of lintuzumab (humanized anti-CD33 antibody; SGN-33, HuM195) was performed in patients with CD33-positive myeloid malignancies. In this study, higher doses than previously tested and prolonged duration of treatment for responding patients were evaluated. Over the dose range of 1.5-8 mg/kg/week, lintuzumab was well tolerated, and a maximum tolerated dose was not defined. The most common adverse event was transient chills with the initial lintuzumab infusion (39%). Responses were observed in 7 of 17 patients with acute myeloid leukemia: morphologic complete remission (n = 4), partial remission (n = 2), and morphologic leukemia-free state (n = 1). Of 14 patients with myelodysplastic syndrome or myeloproliferative diseases, 1 patient had major hematologic improvement and 9 patients had stable disease. In contrast to aggressive conventional chemotherapy, lintuzumab was administered in an ambulatory clinic setting with acceptable toxicity.

• Authors: Azra Raza, Joseph G Jurcic, Gail J Roboz, Michael Maris, Joseph J Stephenson, Brent L Wood, Eric J Feldman, Naomi Galili, Laurie E Grove, Jonathan G Drachman, Eric L Sievers
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 50 Issue 8 Pg. 1336-44 (Aug 2009) ISSN: 1029-2403 [Electronic] United States
• PMID: 19557623 (Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antigens, CD
• Antigens, Differentiation, Myelomonocytic
• Antigens, Neoplasm
• Antineoplastic Agents
• CD33 protein, human
• Sialic Acid Binding Ig-like Lectin 3
• lintuzumab

Topics

• Acute Disease
• Aged
• Aged, 80 and over
• Antibodies, Monoclonal (administration & dosage, adverse effects, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antigens, CD (immunology)
• Antigens, Differentiation, Myelomonocytic (immunology)
• Antigens, Neoplasm (immunology)
• Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
• Chills (chemically induced)
• Dose-Response Relationship, Drug
• Fatigue (chemically induced)
• Female
• Fever (chemically induced)
• Humans
• Infusions, Intravenous
• Leukemia, Myeloid (drug therapy)
• Male
• Middle Aged
• Myelodysplastic Syndromes (drug therapy)
• Myeloproliferative Disorders (drug therapy)
• Remission Induction
• Sialic Acid Binding Ig-like Lectin 3